Vermillion, Inc. (NASDAQ:VRML) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 982,035 shares, a growth of 27.9% from the August 31st total of 767,768 shares. Currently, 3.1% of the shares of the stock are short sold. Based on an average daily volume of 43,840 shares, the short-interest ratio is presently 22.4 days.

Shares of Vermillion (NASDAQ:VRML) opened at 1.65 on Tuesday. Vermillion has a 52 week low of $0.76 and a 52 week high of $2.85. The firm’s market capitalization is $92.67 million. The firm has a 50 day moving average price of $1.36 and a 200-day moving average price of $1.69.

Vermillion (NASDAQ:VRML) last posted its earnings results on Wednesday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $0.90 million for the quarter. Vermillion had a negative return on equity of 215.26% and a negative net margin of 372.05%. Equities research analysts predict that Vermillion will post ($0.16) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. M&T Bank Corp raised its holdings in shares of Vermillion by 48.2% in the first quarter. M&T Bank Corp now owns 230,500 shares of the company’s stock worth $482,000 after acquiring an additional 75,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Vermillion by 0.7% in the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock valued at $1,068,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Oracle Investment Management Inc. lifted its position in shares of Vermillion by 7.2% in the first quarter. Oracle Investment Management Inc. now owns 9,241,956 shares of the company’s stock valued at $19,316,000 after acquiring an additional 617,731 shares in the last quarter. 35.57% of the stock is owned by institutional investors.

Several equities research analysts recently commented on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $1.75 price target (down previously from $2.50) on shares of Vermillion in a report on Wednesday, August 30th. ValuEngine lowered Vermillion from a “hold” rating to a “sell” rating in a research note on Friday, July 28th.

ILLEGAL ACTIVITY NOTICE: “Vermillion, Inc. (VRML) Short Interest Update” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at

About Vermillion

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.